Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities

Oncology Reports

Volumn 22, Issue 2, 2009, Pages 355-360

  Noguchi, Ryuichi ^a   Yoshiji, Hitoshi ^a   Ikenaka, Yasuhide ^a   Namisaki, Tadashi ^a   Kitade, Mitsuteru ^a   Kaji, Kosuke ^a   Yoshii, Junichi ^a   Yanase, Koji ^a   Yamazaki, Masaharu ^a   Tsujimoto, Tatsuhiro ^a   Kawaratani, Hideto ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Angiotensin; Gemcitabine; Pancreatic tumor; VEGF

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GEMCITABINE; LOSARTAN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; DEOXYCYTIDINE; DRUG SYNERGISM; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68349096413     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000445     Document Type: Article

References (45)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
2. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
3. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
4. Burris H and Storniolo AM: Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33 (Suppl. 1): S18-S22, 1997.
5. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM and von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-353, 1996.
6. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.
7. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
8. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki S and Chayama K: Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 26: 344-349, 2003.
9. Khan AW, Dhillon AP, Hutchins R, Abraham A, Shah SR, Snooks S and Davidson BR: Prognostic significance of intratumoural microvessel density (IMD) in resected pancreatic and ampullary cancers to standard histopathological variables and survival. Eur J Surg Oncol 28: 637-644, 2002.
10. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H and Miyake M: Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79: 1553-1563, 1999.
11. Laquente B, Lacasa C, Ginesta MM, Casanovas O, Figueras A, Galan M, Ribas IG, Germa JR, Capella G and Vinals F: Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 7: 638-647, 2008.
12. Jia L, Zhang MH, Yuan SZ and Huang WG: Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol 11: 447-450, 2005.
13. Zhang X, Galardi E, Duquette M, Lawler J and Parangi S: Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res 11: 5622-5630, 2005.
14. Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R and Ellis LM: Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102: 101-108, 2002.
15. Kerbel RS: Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 19: S45-S51, 2001.
16. Noguchi R, Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Mitoro A, Tsujinoue H, Imazu H, Masaki T and Fukui H: Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9: 6038-6045, 2003.
17. Yoshiji H, Kuriyama S and Fukui H: Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23: 348-356, 2002.
18. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT and Yeo CJ: Antihypertensives as novel antineoplastics: angiotensin-Iconverting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204: 996-1006, 2007.
19. Fujimoto Y, Sasaki T, Tsuchida A and Chayama K: Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495: 197-200, 2001.
20. Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR and Grindey GB: Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5: 223-228, 1993.
21. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T and Remuzzi G: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4: 40-49, 1993.
22. Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H and Fukui H: KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30: 1179-1186, 1999.
23. Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R, Okuda H, Tsujinoue H, Nakatani T, Kishida H, Nakae D, Gomez DE, De Lorenzo MS, Tejera AM and Fukui H: The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer 94: 768-773, 2001.
24. Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26: 25-35, 2001.
25. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H: The angiotensin-i-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7: 1073-1078, 2001.
26. Saif MW: Anti-angiogenesis therapy in pancreatic carcinoma. JOP 7: 163-173, 2006.
27. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
28. Scappaticci FA, Smith R, Pathak A, Schloss D, Lum B, Cao Y, Johnson F, Engleman EG and Nolan GP: Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 3: 186-196, 2001.
29. Muramaki M, Miyake H, Hara I, Kawabata G and Kamidono S: Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model. J Urol 172: 1485-1489, 2004.
30. O'Reilly MS: The combination of antiangiogenic therapy with other modalities. Cancer J 8 (Suppl. 1): S89-S99, 2002.
31. Wang XF, Tu LF, Wang LH and Zhou JY: Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine. J Zhejiang Univ Sci B 7: 837-843, 2006.
32. Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J and Deliconstantinos G: Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects. Anticancer Res 27: 1653-1656, 2007.
33. Rouxel AM, Roguedas AM, Descourt R and Misery L: Handfoot syndrome: A new side effect of erlotinib. Ann Dermatol Venereol 135: 762-764, 2008.
34. Ferrara N: VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 11: 617-624, 2000.
35. Korc M: Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2: 8, 2003.
36. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW and Korc M: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 3: 1309-1316, 1997.
37. Itakura J, Ishiwata T, Shen B, Kornmann M and Korc M: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85: 27-34, 2000.
38. Buchler P, Reber HA, Buchler MW, Friess H and Hines OJ: VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 236: 738-749, 2002.
39. Tahmasebi M, Puddefoot JR, Inwang ER and Vinson GP: The tissue renin-angiotensin system in human pancreas. J Endocrinol 161: 317-322, 1999.
40. Leung PS and Chappell MC: A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol 35: 838-846, 2003.
41. Ohta T, Amaya K, Yi S, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K and Miwa K: Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Int J Oncol 23: 593-598, 2003.
42. Campbell DJ and Habener JF: Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 78: 31-39, 1986.
43. Campbell DJ: Circulating and tissue angiotensin systems. J Clin Invest 79: 1-6, 1987.
44. Storniolo AM, Allerheiligen SR and Pearce HL: Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24: S7-2-S7-7, 1997.
45. Amoh Y, Li L, Tsuji K, Moossa AR, Katsuoka K, Hoffman RM and Bouvet M: Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine. J Surg Res 132: 164-169, 2006.